Plain-English translation of NCT06657131 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing how well [18F]PSMA-1007 (Radelumin®) works as an imaging scan to find prostate cancer that has come back after you've had surgery or radiation. The medication helps doctors see cancer cells more clearly on scans. Researchers want to understand how accurate and helpful this scan is in everyday medical practice.
Prostate cancer can sometimes return after initial treatment, and doctors need better ways to find it early. This study will gather real-world information about how well this medication works in actual clinical settings, which could help improve how doctors care for men with recurring prostate cancer.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive the imaging scan using this new medication as part of your regular medical care. Researchers will collect information about how well the scan finds cancer and how it affects your treatment decisions. The study will gather high-quality data that may eventually help doctors use artificial intelligence to improve cancer detection in the future.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
Germany
Sponsor
Heinrich-Heine University, Duesseldorf
Enrollment target
~250 participants
Started
November 2024
Primary completion
November 2026
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Emil Novruzov, Medical Doctor
Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.